Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis

Click to increase image sizeClick to decrease image sizeKeywords: AL amyloidosisamyloid depositionbone marrow biopsyabdominal subcutaneous fat aspiratetarget tissuesurrogate tissue Disclosure statementConflicts of interest EK: Consultancy: Janssen, Pfizer, Amgen Honoraria: Janssen, Pfizer, Takeda, Genesis Pharma, Amgen MG; Honoraria: Janssen, Genesis Pharma, Amgen, Karyopharm, Sanofi, GSK, Takeda, ET; Consultancy: Janssen, Amgen, Genesis Pharma, Celgene, Takeda, Sanofi; Honoraria: Novartis, Janssen, Takeda, Genesis Pharma, Amgen, Celgene, Sanofi, BMS, GSK; MAD: Honoraria: Takeda, BMS, Amgen, Beigene, Janssen. DF, FT, MG, MM, NK, PM, INS, EEP, AP, CK declare no conflicts of interest.Author contributionsDF and EK performed data analysis and research design and wrote the paper. FT, PM, INS, MG, NK, MM and EEP were involved in data collection and patient management and reviewed the manuscript. ET and MAD reviewed the manuscript. AP and CK reviewed the majority of the pathology specimens and reviewed the manuscript.Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.